دانلود کتاب پیشگیری از آلزایمر، درمان قطعی است

Everyone agrees that Alzheimer’s is no way to end one’s life. Although risk increases with age, it is not caused by age as such. This is evident from the many 90+ year olds who have no loss of cognitive function. Fewer than 1% of Alzheimer’s cases are caused by genes. At least half of Alzheimer’s cases could be eliminated by targeting prevention. This is because the hardest hitting known risk factors are largely under your control – what you eat, supplement and how you live. These facts are not disputed. Where the science and the medical ‘establishment’, which includes the pharmaceutical industry, differ is in three areas. The cause, the diagnostic definition and the treatment, as well as the extent to which Alzheimer’s can be prevented. Firstly, the cause. The conventional pharmaceutical view, or spin, is the claim that Alzheimer’s, which makes up two thirds of dementia cases, is caused by a build up of amyloid plaque. This is wrong. A fact that is an inconvenient truth for the pharmaceutical industry, which has spent an estimated £250 billion to develop an amyloid blood test, then a drug to lower it. I’m sure the original intentions of big pharma were true – to find a cure – but having spent so much going down the amyloid rabbit hole, it has become an unhealthy obsession that simply isn’t supported by the science, but might just get a financial return if they can fool enough people and control the medical narrative. The reality is that Alzheimer’s, and most other dementias, are a result of a combination of risk factors that affect either the structure of the brain, how it functions, or how we make use of our neural network. This is not only a completely different way of looking at this disease, known as ‘systems-based’, but it also describes the process of cognitive decline more accurately. The implication is that there is rarely just one cause of damage to the brain, but many that come together to kill off brain cells. It also provides many targets for prevention, and we are discovering how they interact. Pollution exposure, for example, is a risk factor but not in those with good B vitamin status. This doesn’t sit well with the ‘normal’ reductionist model of a randomised-controlled trial, where you change one thing to see it’s effects on one outcome, nor the ‘blockbuster drug’ for all with dementia, ignoring that each person’s drivers for cognitive decline are different. In other words, it necessitates a different method of scientific investigation. This is explained in Chapter 3 – ‘Alzheimer’s is a Systems Breakdown’.